Background: Survivors of cancer diagnosed in childhood, adolescence, or young adulthood (CAY-ACS) risk psychological morbidities later in life. The study compares prescription rates of anxiolytics and hypnotics among survivors to rates in age-and gender-matched controls. Conclusions: Certain groups of CAYACS have an increased risk for being prescribed anxiolytics or hypnotics compared to controls. Diagnostic reasons for prescriptions are unknown, but the results indicate an increased emotional burden among these groups of survivors.
INTRODUCTION
Due to the mental, physical, and emotional stress that cancer treatment entails, the psychological impact can continue for many years after succession of treatment. 1 When cancer strikes in early life, Abbreviations: ATC, Anatomical Therapeutic Chemical; CAYACS, childhood, adolescent, and young adult cancer survivors; CI, confidence interval; CNS, central nervous system; HR, hazard ratio; ICCC, International Classification of Childhood Cancer; ID-number, identification number; NorPD, Norwegian Prescription Database normal development of childhood and adolescence can be affected by the often intensive treatment with need for hospitalizations, isolation from peers and uncertainty regarding future health. 1, 2 Older adolescents and young adults may have problems with establishing identity and developing a positive body image and sexual identity during a period when they normally should be separating from their parents and making decisions about education, careers, and family. 3 In sum, these factors can increase the risk for adjustment problems and adverse psychological outcomes later in life. 2, 3 Survivors of cancer in adolescence or young adulthood may be the group most affected by psychological late effects, as they to a larger degree are able to comprehend the seriousness of the disease. 4 Studies on psychological distress in survivors of cancer in childhood, adolescence, and young adulthood (CAYACS) have yielded inconsistent findings; some have demonstrated increased levels of anxiety and depression among survivors compared to population norms or matched controls, 4-7 whilst others have not found such differences. [8] [9] [10] A few studies have reported increased resilience among CAYACS. 2, [11] [12] [13] The authors presume that these survivors experience cancer as a significant but manageable event that may offer opportunity for coping mastery and more positive view of life and self. 2, 11, 12 These differences in psychological health outcomes may reflect challenges in assessing such outcomes in cancer survivors, since no common assessment method has been established. 14 Standardized interviews are costly and often difficult to administer, resulting in relatively small sample sizes that may lead to biased results. The use of patient-reported outcomes can entail barriers like time and resource constraints and selection bias. 15, 16 Population-based studies of health registry data have the advantage of including well-defined populations, thus eliminating self-selection or recall bias. 17 Additionally, large numbers allow for identification of rare events. 17 Anxiolytics and hypnotics are two of the most commonly prescribed psychotropic medications that relieve anxiety, aid sleep or have a calming effect. 18 Knowledge on the use of these medications among CAY-ACS yields information on how psychological problems are handled and indirectly also on the prevalence of underlying psychological problems. There are few publications on the use of psychotropic medication in CAYACS. Brinkman et al. found increased use of psychotropic medication among childhood cancer survivors compared to their siblings in a questionnaire-based study. 19 In addition, increased prescription rates of antidepressants among CAYACS compared to the general population have been described in register-based studies. [20] [21] [22] The aim of the present report was to study the prescription rates of anxiolytic and hypnotic medication among Norwegian survivors diagnosed with cancer at the age of 0-25 years and compare to the rates in the general population of similar age and gender. We also wanted to study if prescription rates differed between different diagnostic groups of CAYACS.
Based upon the disruption cancer treatment has on normal life, we hypothesized that CAYACS would have a higher prescription rate of anxiolytics or hypnotics than matched controls. We also hypothesized that the prescription rate would increase with increasing age at diagnosis and that survivors of tumors in the central nervous system (CNS) would have the highest prescription rates due to direct treatment to the CNS.
METHODS
The data in the present study were achieved from three national registries: The Cancer Registry of Norway, the Population Registry 
Study population

Cohort of cancer survivors
The study included all patients registered in the Cancer Registry of 
Controls
Statistics Norway supplied three randomly selected age-and gendermatched controls from the Norwegian Population Registry. The controls had to be alive and without cancer and residing in Norway at the time of the survivor's cancer diagnosis. At the start of follow-up on Thirteen controls were found to have had cancer before 25 years of age and were excluded, while cancer diagnosed after age 25 was not an exclusion criterion. In total, 14,855 controls were included in the analyses ( Fig. 1 ).
Psychotropic medications
Anxiolytics are used in the control of anxiety, behavioral agitation, and occasional insomnia. 18 Hypnotics are a class of drugs that induce sleep or depress the CNS at a cortical level. 18 
Analysis strategy and statistical methods
Both cohorts were followed from January 1, 2004 until the first of the following events: first prescription for anxiolytic or hypnotic medication (primary endpoints), emigration, death, or end of study period (December 31, 2012) (Fig. 1) . To be included, the participants had to have at least two independently redeemed prescriptions of anxiolytics or hypnotics during the study period as only one prescription could be caused by short-term distress.
Separate analyses were performed for the two primary outcomes (anxiolytics and hypnotics). Cox regression analyses were also performed separately for each gender.
For the secondary analyses, the effect of age at cancer diagnosis was assessed by using a Cox proportional hazard model, with age attained at start of follow-up in 2004 as a continuous variable. Overall, 717 survivors (13.4%) and 1,435 controls (9.7%) had been prescribed anxiolytics while 869 survivors (16.3%) and 1,718 controls (11.6%) had been prescribed hypnotics during the study period (Table 1) ; 395 (7.4%) survivors and 622 (4.2%) controls had been prescribed both anxiolytics and hypnotics during the follow-up period (P < 0.001).
RESULTS
Cohort characteristics
Prescriptions of anxiolytics
Survivors had higher crude rate for prescriptions of anxiolytics (16.9 /1,000 person years) compared to controls (11.8/1,000 person years) (Table 1 ). 
Prescriptions of hypnotics
The survivors had higher crude rate for prescriptions of hypnotics (20.8/1,000 person years) compared to the controls (14.3/1,000 person years) ( Table 1) . Crude rates according to the cancer type are shown in Table 2 .
The Cox model showed an increased risk of prescription of hypnotics among survivors compared to controls (referent group) (HR 1.44; 95% CI 1.32-1.56) (Fig. 3) . Gastrointestinal tumors, leukemias, and soft tissue cancers had the highest risk and significant estimates.
Male survivors had an HR of 1.52 (95% CI 1.33-1.73) and females had an HR of 1.39 (95% CI 1.25-1.54).
In the secondary analysis, we found no increased risk of anxiolytic or hypnotic prescriptions with increasing age at cancer diagnosis after adjusting for age attained at start of follow-up in 2004.
DISCUSSION
This study reports prescription rates of anxiolytics and hypnotics among CAYACS by using nationwide registries and comparing these rates to prescription rates in a population-based control cohort. The results of the present study support our hypothesis of increased prescription rates of anxiolytic or hypnotic medication to CAYACS compared to controls.
The ability of CAYACS to demonstrate psychological adjustment is well documented. [11] [12] [13] 27 Still, a proportion of survivors report increased psychological problems later in life. 4, 6, 7, 28 Increased use of psychotropic medication among survivors is also reported, indicating an increased need for pharmacological interventions among CAYACS. 19, 20, 22 In the present study, the risk for CAYACS being prescribed anxiolytics or hypnotics was more than 40% higher than in the controls. Without knowing the doctors' therapeutic evaluations for prescribing these psychotropic drugs, the results may indicate that the survivors are more anxious and worried than their peers. Many survivors have reported worries about their future health and possible late effects after the cancer and its treatment. [29] [30] [31] They also often worry about vocational possibilities, fertility problems, and the health of their future children. [32] [33] [34] [35] [36] This applies especially to adolescents and young adults who have experienced a premature confrontation with mortality, changes in physical appearance, and disruptions in social life, and their life perspectives may have changed as a result of their cancer experience. 3, 35 Constant worry can negatively affect both psychological and physical well-being of CAYACS. 37 It can precipitate lower selfesteem, worse self-image, and outlook on life, and unresolved worries can be expressed as somatic complaints. has been shown to increase the risk of worrying. 31, 33 Survivors of gastrointestinal tumors, leukemias, and soft-tissue cancers had the highest risk estimates of prescriptions of hypnotics.
Both anxiolytics and hypnotics are prescribed for anxiety and/or sleep problems. 40 Mulrooney et al. found that childhood cancer survivors, including survivors of acute lymphatic leukemia, soft-tissue sarcomas, bone cancers, and brain tumors, had poorer sleep quality and increased daytime sleepiness compared to their siblings. 41 A significantly higher proportion of survivors got prescriptions from both groups of psychotropic medications that may suggest a greater symptom burden in survivors compared to controls.
Female survivors were more often prescribed anxiolytics and hypnotics than male survivors. This also applied to the controls and is compatible with what is seen in the general population. 42 Still, with higher HR, the risk of prescription seems to be higher for men.
Cancer diagnosed in adolescence or young adulthood has been shown to have a greater impact on later psychological health than if the disease strikes in preschool age. 4, 28 However, as observed in our study on antidepressants prescriptions, age at diagnosis did not seem to have an effect on prescription rates. 22 A major strength of this study is the use of population-based registries. All Norwegian citizens have their unique identification number (ID-number) and can therefore be tracked in the registries by their encrypted ID-number, which enables a comprehensive follow-up.
Linking large administrative databases enables the creation of a large cohort that can give more power to late effect studies among CAYACS.
One limitation of the present study is that the NorPD was 
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